Mergers & Acquisitions
Beyond the Balance Sheet: The Air India Crash Allegations and a Sobering Lesson in Investment Risk
Allegations of safety defects on a crashed Air India plane offer a stark lesson on the hidden financial risks of corporate acquisitions and their market impact.
Netflix Goes All-In: The All-Cash Gambit to Conquer Warner Bros. Discovery and Reshape Hollywood
Netflix escalates the bidding war for Warner Bros. Discovery with a bold all-cash offer, a strategic move to outmaneuver rivals and reshape Hollywood.
Clash of Titans: Why Elliott Management is Blocking Toyota’s $34 Billion Corporate Maneuver
Activist investor Elliott Management rejects Toyota’s $34bn take-private offer for a subsidiary, sparking a major battle over corporate value and governance.
Beyond the Bottle: Kikkoman’s Multi-Billion Dollar Recipe for Global Dominance
Kikkoman, the iconic soy sauce maker, is shifting from organic growth to a bold M&A strategy to combat a shrinking domestic market in Japan.
Netflix’s Ultimate Endgame: Why a Warner Bros. Bid is a High-Stakes Play for AI and Cloud Dominance
Netflix’s potential bid for Warner Bros. isn’t just about content; it’s a strategic tech play involving AI, cloud infrastructure, and software automation.
Titans in Transition: A Spanish Power Play, a Retail Reckoning, and AIG’s High-Stakes Bet
A deep dive into a major Spanish M&A deal, the collapse of Saks Global, and AIG’s bold return to risk-taking in the financial markets.
The Ultimate M&A Deal: A Finance Playbook for Acquiring a Country
Applying a corporate M&A framework to the hypothetical purchase of Greenland reveals fascinating insights into geopolitics, finance, and national valuation.
Giants on the Move: Decoding High-Stakes Plays in Mining, Pharma, and Finance
Dissecting major strategic moves by Glencore, Rio Tinto, Merck, and hedge funds, and what they signal for the future of investing and the global economy.
Merck’s $32 Billion Gambit: Decoding the High-Stakes Pursuit of a Cancer-Fighting Pioneer
Merck’s potential $32bn acquisition of Revolution Medicines signals a major shift in the oncology market. A deep dive into the finance and science behind the deal.
The 3% Illusion: Why a Minor Correction in Sinochem’s Pirelli Stake Reveals Major Truths About Global Finance
A minor 3% correction in Sinochem’s Pirelli stake reveals major truths about corporate governance, geopolitical risk, and the need for data integrity.
Hollywood’s High-Stakes Choice: Why Warner Bros. is Betting its Future on Netflix, Not Paramount
Warner Bros. Discovery’s board rejects Paramount’s “inferior” offer, championing a strategic deal with Netflix in a pivotal move for the media industry.
The $22 Billion Energy Gambit: Chevron and a PE Giant Eye a Sanctioned Russian Prize
A look at the $22bn bid by Chevron and Quantum Energy Partners for sanctioned Russian oil giant Lukoil’s international assets, a major geopolitical move.